Pfizer Inc.(PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest News & Analysis
Pfizer (PFE): Navigating Legal Hurdles, Stock Volatility, and Future Growth
Pfizer (PFE) faces challenges but the GSK lawsuit resolution and cost-cutting offer upsides. High dividend yield may attract investors, but volatility and tariffs warrant caution.
Pfizer (PFE): ABRYSVO Approval, Tariff Risks, and Dividend Dilemma
Pfizer Inc. (PFE) navigates EU approval of ABRYSVO, tariff threats, and dividend sustainability concerns amid ETF shifts. A deep dive into PFE's strategic response.
Pfizer (PFE): Strategic Shift, Pipeline Focus, and Growth Outlook
Pfizer's strategic shift, pipeline focus, and dividend appeal analyzed. Learn how these factors shape its growth outlook and investment potential.
Pfizer (PFE): Strategic Shifts, Dividend Outlook, and Growth
Pfizer (PFE) navigates strategic shifts, a compelling dividend, and growth challenges. This analysis explores valuation, market sensitivity, and strategies to mitigate trade war risks.
Pfizer's Strategic Reset: Haleon Divestiture, China Expansion, and Dividend Outlook
Pfizer navigates strategic shifts: Haleon divestiture, China expansion, and dividend sustainability in a dynamic pharmaceutical landscape.
Pfizer (PFE): Sales, China, and Apretude Strategy Analysis
Pfizer (PFE) navigates post-pandemic market via sales revamp, China focus, Apretude. Financial analysis reveals fluctuating profitability. Valuation gap suggests undervaluation. Investors monitor catalysts.
Pfizer (PFE): Oncology Breakthroughs, Financial Resilience, Dividend
Pfizer Inc. (PFE) navigates oncology breakthroughs, financial resilience, and dividend sustainability amidst challenges. Strategic collaborations and cost-cutting are crucial.
Pfizer Inc.: Intraday Updates and Key Developments
Pfizer intraday update reveals robust revenue growth, dividend strength and legal challenges shaping its strategic trajectory.
Pfizer's Strategic Shift: Oncology Focus & Vaccine Pipeline
Pfizer strategically focuses on oncology via collaborations like Summit Therapeutics, navigating regulatory changes and new coronavirus variants. Legal challenges and vaccine demand present risks.
Pfizer: Oncology Strategy, Regulatory Changes, and Market Outlook
Pfizer focuses on oncology via collaborations, addresses coronavirus concerns, and faces a Depo-Provera probe. Cavazzoni's CMO role could streamline approvals, while value stocks gain traction.
Pfizer's Strategic Shift: Oncology, Regulatory Expertise, and Dividend Prospects
Pfizer focuses on oncology with Ivonescimab, appoints Patrizia Cavazzoni as CMO, and navigates vaccine demand and legal challenges, maintaining investor appeal.
Pfizer's Strategic Shift: Pipeline Adjustments and Market Impact
A comprehensive, data-driven update on Pfizer Inc.'s strategic pivot, pipeline realignment, legal investigations, and market challenges.
Pfizer's Strategic Pivot: Gene Therapy Setback and Oncology Focus
Pfizer navigates strategic shifts, ending gene therapy development while focusing on oncology amid legal scrutiny, impacting investor sentiment and future prospects.
Pfizer: Navigating Oncology, Dividends, and Regulatory Challenges in 2025
A detailed data-driven update on Pfizer’s latest developments, clinical breakthroughs, and regulatory challenges affecting [PFE](/dashboard/companies/PFE).
Pfizer Faces Scrutiny Amidst Drug Developments & Headwinds
A comprehensive intraday analysis of Pfizer covering legal scrutiny, breakthrough clinical trials, dividend yields, and strategic market responses.